drugset / Trial / NCT03436394

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

NCT03436394

Phase 1 Completed 31 enrolled Merck KGaA, Darmstadt, Germany
Non-randomizedParallel-groupOpen-labelOther

Summary

The study will investigate the PK and safety of evobrutinib in subjects with different degree of renal impairment as compared to subjects with normal renal function.

Timeline

Start
2018-03-21
Primary completion
2019-02-22
Completion
2019-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Evobrutinib Small molecule Oral